Prognostic Comparison between Oncotype DX^® and a 23-Gene Classifier, RecurIndex^®, on the Taiwan Breast Cancer Population.

ABSTRACT: The applicability of the Oncotype DX^® (Genomic Health, Inc., Redwood City, CA, USA) recurrence score (RS) in Asian populations is unclear. A 23-gene classifier, RecurIndex^® (Amwise Diagnostics, Pte. Ltd., Singapore), has been developed based on the gene expression profiles of early-stage breast cancer patients of ethnic Han Chinese population in Taiwan. This study aimed to compare the performance of the Oncotype DX^® RS with the RecurIndex^® recurrence index (RI) for predicting relapse-free survival. Therefore, we calculated both the RI and RS for 110 early stage breast cancer patients, with the cut-off value for high-risk recurrence set at 26 and 29 for the RS and the RI, respectively. With relapse-free interval (RFI) as the primary endpoint, the

SUBMITTER: Chang CH 

PROVIDER: S-EPMC9689820 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature